A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Revolution Medicines presented the Phase 3 trial data on May 31, 2026. The study involved 500 patients with metastatic pancreatic cancer who had already received prior treatment. Daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months on standard chemotherapy. The therapy also lowered the risk of death by 60 percent. Patients reported better quality of life and were less likely to discontinue treatment because of severe side effects. The most frequent adverse events included skin rash in more than 86 percent of participants along with mouth sores, diarrhea, nausea, and vomiting. Daraxonrasib works by binding to cyclophilin A to block the KRAS protein that drives most pancreatic tumors. The company plans to seek regulatory approval from the Food and Drug Administration and other agencies. If approved, the drug could become available to patients within months.
